KRYS News

Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis

Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis

Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results

Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis